TILT-322

N/A

Report date: 2026/03/19 17:15:11

Base Information

Drug NameTILT-322
Drug Alias NameAd5/3-E2F-d24-aMUC1aCD3-IL-2TILT-322
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInterleukin-2 agonistsMucin-1 modulatorsT cell surface glycoprotein CD3 modulators
TargetsInterleukin-2Mucin-1T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFinland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTilt Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTilt Biotherapeutics LtdUniversity Of Helsinki
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A